Treace Medical Concepts (NASDAQ:TMCI) is gearing up to announce its quarterly earnings on Friday, 2026-02-27. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Treace Medical Concepts will report an earnings per share (EPS) of $-0.14.

Treace Medical Concepts bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Performance in Previous Earnings

Last quarter the company beat EPS by $0.01, which was followed by a 28.33% drop in the share price the next day.

Here's a look at Treace Medical Concepts's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.27	-0.29	-0.30	-0.04
EPS Actual	-0.26	-0.28	-0.25	-0.01
Price Change %	-28.33	7.92	-9.55	-2.08

Market Performance of Treace Medical Concepts's Stock

Shares of Treace Medical Concepts were trading at $2.04 as of February 25. Over the last 52-week period, shares are down 77.35%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

About Treace Medical Concepts

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

Breaking Down Treace Medical Concepts's Financial Performance

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Positive Revenue Trend: Examining Treace Medical Concepts's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.37% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: Treace Medical Concepts's net margin excels beyond industry benchmarks, reaching -32.44%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Treace Medical Concepts's ROE excels beyond industry benchmarks, reaching -17.44%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Treace Medical Concepts's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -8.08%, the company showcases efficient use of assets and strong financial health.

Debt Management: Treace Medical Concepts's debt-to-equity ratio is below the industry average. With a ratio of 0.79, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

To track all earnings releases for Treace Medical Concepts visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.